X4 Pharmaceuticals, Inc. XFOR · Stock Open X4 Pharmaceuticals, Inc. in new tab
X4 Pharmaceuticals, Inc. Analysis (XFOR)
Is X4 Pharmaceuticals, Inc. a good investment? X4 Pharmaceuticals, Inc. (XFOR) is currently trading at 4.09 USD. Market analysts have a consensus price target of 11.60 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.67. This relatively low multiple may signal that X4 Pharmaceuticals, Inc. is undervalued compared to historical market norms.
Earnings Schedule: X4 Pharmaceuticals, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.82.
Investor FAQ
Does X4 Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is X4 Pharmaceuticals, Inc.?
X4 Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -2.07.
Company Profile
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| March 14, 2019 | 0.170000 |
| April 28, 2025 | 0.030000 |
Community Discussion